Inflammatory Index as a Predictor for Endometrial Cancer: an Observational Study

Launched by UNIVERSITY OF CAMPANIA LUIGI VANVITELLI · Dec 10, 2022

Keywords

ClinConnect Summary

This clinical trial is studying how certain markers of inflammation in the body might help predict the risk of endometrial cancer in women. Inflammation can be measured in different ways, and this trial specifically looks at three ratios: the neutrophil-to-lymphocyte ratio (NLR), the platelet-to-lymphocyte ratio (PLR), and the lymphocyte-to-monocyte ratio (MRL). The goal is to see if changes in these ratios can help classify the risk of patients according to existing guidelines in Europe.

Women aged 18 and older who have been diagnosed with endometrial cancer and are planning to have surgery may be eligible to participate. Participants will be asked to give their consent to join the study and will receive a full-body CT scan within 30 days before joining. It's important to note that those with certain chronic inflammatory diseases, recent cancer diagnoses, or those on steroid therapy might not be able to participate. If you choose to take part, you'll help researchers better understand the connection between inflammation and endometrial cancer, which could lead to improved care for future patients.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Patients histologically diagnosed with endometrial cancer.
• • Patients undergoing surgical staging of the disease.
• • Patients undergoing full-body CT-scan 30 days before enrollment.
• • At least 18-year-old patients.
• Exclusion Criteria:
• • Unfit to plead.
• • Patients with chronic inflammatory diseases (IBDs; rheumatic conditions).
• • Synchronous tumors or cancer diagnosis in the previous 3 years.
• • Patients undergoing steroid therapy in the last 30 days prior to recruitment

Trial Officials